$24.03
0.02[0.08%]
Last update: 1:07PM Get Real Time Here
Arrowhead Pharma
(NASDAQ:ARWR)Arrowhead Pharma Stock (NASDAQ:ARWR), Analyst Ratings, Price Targets, Predictions
Arrowhead Pharmaceuticals Inc has a consensus price target of $49.61, established from looking at the 55 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., Morgan Stanley, and Citigroup on February 8, 2024, February 7, 2024, and February 7, 2024. With an average price target of $53.33 between HC Wainwright & Co., Morgan Stanley, and Citigroup, there's an implied 121.94% upside for Arrowhead Pharmaceuticals Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Morgan Stanley
Citigroup
RBC Capital
B of A Securities
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Arrowhead Pharma
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 02/08/2024 | ARWR | Buy Now | Arrowhead Pharma | $24.03 | 274.53% | HC Wainwright & Co. | Patrick Trucchio | → $90 | Reiterates | Buy → Buy | Get Alert |
| 02/07/2024 | ARWR | Buy Now | Arrowhead Pharma | $24.03 | 49.81% | Morgan Stanley | Michael Ulz | $34 → $36 | Maintains | Equal-Weight | Get Alert |
| 02/07/2024 | ARWR | Buy Now | Arrowhead Pharma | $24.03 | 41.49% | Citigroup | Shawn Egan | $33 → $34 | Maintains | Neutral | Get Alert |
| 02/07/2024 | ARWR | Buy Now | Arrowhead Pharma | $24.03 | 108.07% | RBC Capital | Luca Issi | → $50 | Reiterates | Outperform → Outperform | Get Alert |
| 01/16/2024 | ARWR | Buy Now | Arrowhead Pharma | $24.03 | 108.07% | RBC Capital | Luca Issi | → $50 | Reiterates | Outperform → Outperform | Get Alert |
| 01/02/2024 | ARWR | Buy Now | Arrowhead Pharma | $24.03 | 53.97% | B of A Securities | Jason Gerberry | $29 → $37 | Maintains | Buy | Get Alert |
| 12/04/2023 | ARWR | Buy Now | Arrowhead Pharma | $24.03 | 20.68% | B of A Securities | Jason Gerberry | → $29 | Initiates | → Buy | Get Alert |
| 11/30/2023 | ARWR | Buy Now | Arrowhead Pharma | $24.03 | 53.97% | Morgan Stanley | Michael Ulz | $40 → $37 | Maintains | Equal-Weight | Get Alert |
| 11/30/2023 | ARWR | Buy Now | Arrowhead Pharma | $24.03 | 108.07% | RBC Capital | Luca Issi | → $50 | Reiterates | Outperform → Outperform | Get Alert |
| 09/19/2023 | ARWR | Buy Now | Arrowhead Pharma | $24.03 | 37.33% | Citigroup | Shawn Egan | → $33 | Initiates | → Neutral | Get Alert |
| 08/09/2023 | ARWR | Buy Now | Arrowhead Pharma | $24.03 | 274.53% | HC Wainwright & Co. | Patrick Trucchio | → $90 | Reiterates | Buy → Buy | Get Alert |
| 08/08/2023 | ARWR | Buy Now | Arrowhead Pharma | $24.03 | 149.69% | Chardan Capital | Keay Nakae | → $60 | Reiterates | Buy → Buy | Get Alert |
| 08/08/2023 | ARWR | Buy Now | Arrowhead Pharma | $24.03 | 95.59% | Cantor Fitzgerald | Alethia Young | $79 → $47 | Maintains | Overweight | Get Alert |
| 08/08/2023 | ARWR | Buy Now | Arrowhead Pharma | $24.03 | 149.69% | RBC Capital | Luca Issi | → $60 | Reiterates | Outperform → Outperform | Get Alert |
| 07/21/2023 | ARWR | Buy Now | Arrowhead Pharma | $24.03 | — | TD Cowen | Brendan Smith | — | Initiates | → Outperform | Get Alert |
| 07/20/2023 | ARWR | Buy Now | Arrowhead Pharma | $24.03 | 128.88% | B. Riley Securities | Mayank Mamtani | → $55 | Reiterates | Buy → Buy | Get Alert |
| 06/30/2023 | ARWR | Buy Now | Arrowhead Pharma | $24.03 | 274.53% | HC Wainwright & Co. | Patrick Trucchio | → $90 | Reiterates | Buy → Buy | Get Alert |
| 06/06/2023 | ARWR | Buy Now | Arrowhead Pharma | $24.03 | 274.53% | HC Wainwright & Co. | Patrick Trucchio | → $90 | Reiterates | Buy → Buy | Get Alert |
| 06/02/2023 | ARWR | Buy Now | Arrowhead Pharma | $24.03 | 145.53% | Piper Sandler | Edward Tenthoff | $52 → $59 | Maintains | Overweight | Get Alert |
FAQ
What is the target price for Arrowhead Pharma (ARWR)?
The latest price target for Arrowhead Pharma (NASDAQ: ARWR) was reported by HC Wainwright & Co. on February 8, 2024. The analyst firm set a price target for $90.00 expecting ARWR to rise to within 12 months (a possible 274.53% upside). 26 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Arrowhead Pharma (ARWR)?
The latest analyst rating for Arrowhead Pharma (NASDAQ: ARWR) was provided by HC Wainwright & Co., and Arrowhead Pharma reiterated their buy rating.
When was the last upgrade for Arrowhead Pharma (ARWR)?
The last upgrade for Arrowhead Pharmaceuticals Inc happened on April 12, 2023 when SVB Securities raised their price target to $35. SVB Securities previously had a market perform for Arrowhead Pharmaceuticals Inc.
When was the last downgrade for Arrowhead Pharma (ARWR)?
The last downgrade for Arrowhead Pharmaceuticals Inc happened on May 12, 2023 when SVB Leerink changed their price target from N/A to $40 for Arrowhead Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for Arrowhead Pharma (ARWR)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Arrowhead Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Arrowhead Pharma was filed on February 8, 2024 so you should expect the next rating to be made available sometime around February 8, 2025.
Is the Analyst Rating Arrowhead Pharma (ARWR) correct?
While ratings are subjective and will change, the latest Arrowhead Pharma (ARWR) rating was a reiterated with a price target of $0.00 to $90.00. The current price Arrowhead Pharma (ARWR) is trading at is $24.03, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.